China Pharma Holdings (CPHI) stock price, revenue, and financials

China Pharma Holdings market cap is $21.6 m, and annual revenue was $10.92 m in FY 2019

$21.6 M

CPHI Mkt cap, 21-Oct-2020

$3.8 M

China Pharma Holdings Revenue Q2, 2020
China Pharma Holdings Gross profit (Q2, 2020)1.1 M
China Pharma Holdings Gross profit margin (Q2, 2020), %30.5%
China Pharma Holdings Net income (Q2, 2020)13.1 K
China Pharma Holdings EBIT (Q2, 2020)75 K
China Pharma Holdings Cash, 30-Sept-2019761.6 K

China Pharma Holdings Revenue

China Pharma Holdings revenue was $10.92 m in FY, 2019

Embed Graph

China Pharma Holdings Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q4, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

19.6m21.0m81.2m16.1m14.6m12.2m8.2m8.0m8.1m7.1m6.1m5.6m5.7m5.7m4.5m3.6m3.5m3.1m3.3m2.9m3.2m3.6m3.2m2.3m2.9m2.6m2.4m1.8m3.8m

Cost of goods sold

12.3m13.5m52.2m10.8m10.5m8.9m6.1m5.8m5.9m4.4m3.7m4.1m4.4m4.5m3.7m3.1m2.9m2.7m2.6m2.3m2.7m2.6m2.6m1.8m2.3m2.4m2.0m1.6m2.6m

Gross profit

7.3m7.5m29.0m5.3m4.1m3.2m2.1m2.2m2.3m2.7m2.4m1.5m1.3m1.2m758.7k569.0k674.2k429.7k717.9k648.4k421.5k1.1m579.5k512.5k656.5k163.5k372.8k194.4k1.1m

Gross profit Margin, %

37%36%36%33%28%27%26%27%28%37%39%27%22%20%17%16%19%14%22%22%13%29%18%22%22%6%16%11%30%

Sales and marketing expense

799.2k1.0m3.4m894.1k881.9k856.2k812.1k701.7k921.9k820.4k627.4k746.0k989.0k1.0m1.2m968.5k857.7k927.2k717.6k803.4k686.8k678.3k716.2k925.7k478.7k505.9k613.1k326.1k727.6k

R&D expense

160.8k174.9k405.4k93.4k96.7k99.1k26.1k21.5k27.5k22.2k23.7k62.1k69.9k66.0k39.7k48.8k30.0k

General and administrative expense

986.9k621.3k3.7m676.4k812.7k598.3k739.4k1.5m725.2k423.9k382.8k422.7k472.4k459.0k384.4k318.9k781.0k294.4k416.7k612.0k349.0k492.0k353.1k327.2k428.8k334.6k333.8k388.6k322.4k

Operating expense total

1.5m1.6m7.0m1.9m1.9m1.6m1.4m6.9m4.9m5.0m10.9m7.5m4.8m(1.5m)(2.9m)2.0m2.7m1.9m1.5m2.8m2.5m1.2m1.4m2.4m990.7k916.5k1.0m793.7k1.1m

EBIT

5.8m6.0m22.0m3.4m2.2m1.6m(3.0m)(4.8m)(2.7m)(2.3m)(8.5m)(6.0m)(3.8m)1.4m3.2m(1.3m)(2.2m)(1.5m)(802.6k)(2.1m)(2.1m)(140.7k)(864.4k)(1.9m)(334.2k)(753.0k)(645.2k)(599.3k)75.0k

EBIT margin, %

29%28%27%21%15%13%(36%)(59%)(33%)(33%)(139%)(108%)(66%)25%71%(36%)(63%)(50%)(24%)(73%)(65%)(4%)(27%)(84%)(11%)(29%)(27%)(34%)2%

Interest expense

61.2k62.4k255.2k77.5k78.5k79.5k82.4k92.0k89.2k56.4k113.4k325.2k313.8k322.4k279.1k139.0k121.1k85.6k83.5k85.1k55.8k

Interest income

2.5k1.2k7.2k690.0791.01.6k1.6k1.0k2.2k21.8k8.8k26.9k30.2k36.2k33.6k33.1k32.4k5.0k16.3k21.9k2.3k9.5k16.1k3.3k12.1k11.8k386.01.2k

Pre tax profit

198.0k5.9m686.3k3.3m2.1m1.5m(3.1m)(4.9m)(2.8m)(2.4m)(8.6m)(6.3m)(4.1m)1.1m3.0m(1.5m)(2.4m)(1.7m)(936.6k)(2.3m)(2.2m)(267.5k)(985.5k)(2.0m)(417.7k)(838.1k)(701.0k)(660.9k)13.1k

Income tax expense

(888.9k)(927.8k)(3.4m)(530.6k)(372.9k)(244.5k)269.0k388.0k472.5k(19.3k)19.2k(19.2k)(19.3k)(19.4k)(18.9k)(20.8k)30.6k31.2k26.0k22.6k(160.5k)

Net Income

5.1m5.0m19.3m2.8m1.8m1.3m(2.8m)(4.5m)(2.3m)(2.4m)(8.6m)(6.3m)(4.1m)1.1m2.9m(1.6m)(2.5m)(1.7m)(966.9k)(2.3m)(2.2m)(293.5k)(1.0m)(1.9m)(417.7k)(838.1k)(701.0k)(660.9k)13.1k

China Pharma Holdings Balance Sheet

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

4.0m6.0m5.3m6.2m2.7m1.2m

Accounts Receivable

66.2m45.1m24.9m5.9m

Prepaid Expenses

339.1k

Inventories

36.4m24.7m15.3m9.7m7.3m5.1m

Current Assets

112.5m84.0m54.5m25.0m17.5m8.7m

PP&E

9.0m30.2m33.9m29.4m25.0m19.3m

Total Assets

163.2m157.6m132.1m97.2m78.5m45.4m

Accounts Payable

2.8m1.9m2.6m2.8m3.1m1.1m

Short-term debt

4.8m8.7m9.1m9.0m

Current Liabilities

14.6m12.0m14.2m12.8m10.4m10.1m

Total Debt

4.8m8.7m9.1m9.0m

Total Liabilities

14.7m24.7m25.8m24.6m19.6m15.2m

Common Stock

43.6k43.6k43.6k43.6k

Preferred Stock

Additional Paid-in Capital

23.6m23.6m23.6m23.6m23.6m23.6m

Retained Earnings

108.9m88.9m62.8m33.9m24.8m

Total Equity

148.5m132.9m106.3m72.6m58.9m43.6k30.2m

Debt to Equity Ratio

0 x0.1 x0.1 x0.1 x

Debt to Assets Ratio

0 x0.1 x0.1 x0.1 x

Financial Leverage

1.1 x1.2 x1.2 x1.3 x1.3 x1.5 x

Quarterly

USDQ2, 2011Q3, 2011Q4, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

4.7m4.9m4.1m3.3m4.9m5.1m4.8m2.5m4.5m5.3m4.4m4.3m5.3m4.5m5.7m7.3m6.3m3.7m2.5m1.7m1.1m2.5m1.9m667.6k961.3k1.7m761.6k

Accounts Receivable

66.1m68.7m69.7m73.5m71.4m69.8m62.7m55.4m541.1k42.3m35.9m30.6m250.2k11.4m419.0k192.0k171.9k390.5k272.1k3.2m2.9m

Prepaid Expenses

231.6k58.1k195.1k47.3k259.2k205.3k185.5k168.1k

Inventories

24.0m26.6m30.4m34.3m36.4m37.8m33.3m33.7m32.6m22.9m21.0m19.0m15.3m13.6m12.3m9.9m8.9m8.6m7.0m7.3m6.8m6.4m6.4m6.1m4.9m4.4m4.0m

Current Assets

101.0m106.2m110.6m117.1m118.2m118.7m108.2m101.1m98.3m77.9m69.0m63.6m41.0m38.5m36.1m25.1m23.8m21.0m17.5m17.2m15.0m13.6m13.1m9.7m8.2m7.7m6.2m

PP&E

6.3m6.2m6.3m6.2m6.0m5.8m9.3m15.4m20.6m33.5m34.1m33.9m33.2m32.6m30.5m28.8m27.2m26.3m24.4m24.1m24.2m23.6m21.6m20.1m19.1m17.9m16.7m

Total Assets

143.4m150.9m156.4m163.6m164.9m166.0m159.3m158.9m162.5m154.3m146.0m140.5m118.0m115.4m108.9m97.0m92.0m87.4m78.1m77.1m75.0m62.1m58.3m52.5m45.2m43.0m39.9m

Accounts Payable

2.8m3.1m3.1m5.9m4.9m4.8m3.0m4.3m3.3m2.2m2.5m3.1m3.2m3.7m4.3m3.7m2.9m3.5m2.9m2.1m1.9m1.4m1.2m588.7k1.1m1.3m1.2m

Short-term debt

3.9m3.9m3.9m4.0m4.0m4.0m4.8m4.9m8.3m4.9m4.9m4.9m9.2m9.3m9.1m9.1m8.9m6.7m1.3m2.3m

Current Liabilities

12.3m13.2m13.8m17.3m16.6m16.5m12.6m14.5m13.0m11.7m11.9m14.3m14.7m14.4m16.1m14.1m14.1m13.0m10.5m10.5m10.4m9.7m9.7m9.8m9.2m9.0m9.6m

Total Debt

3.9m3.9m3.9m4.0m4.0m4.0m4.8m4.9m8.3m4.9m4.9m4.9m9.2m9.3m9.1m9.1m8.9m6.7m1.3m2.3m

Total Liabilities

12.4m13.3m13.9m17.4m16.7m16.7m12.7m14.7m19.6m24.9m25.1m25.9m29.6m28.8m28.3m25.5m25.0m22.5m19.7m20.0m18.0m17.7m17.3m14.9m14.6m14.1m12.5m

Common Stock

43.5k43.5k43.5k43.5k43.6k43.6k43.6k43.6k43.6k43.6k43.6k43.6k43.6k43.6k43.6k43.6k43.6k43.6k43.6k43.6k43.6k

Preferred Stock

Additional Paid-in Capital

23.3m23.4m23.4m23.5m23.6m23.6m23.6m23.6m23.6m23.6m23.6m23.6m23.6m23.6m23.6m23.6m23.6m23.6m23.6m23.6m23.6m23.6m23.6m23.6m23.6m23.6m23.6m

Retained Earnings

95.2m100.2m104.3m107.1m108.9m110.1m106.1m101.6m99.3m86.5m77.9m71.5m44.6m42.5m40.2m32.4m29.9m28.2m23.8m21.5m19.3m5.2m4.2m2.3m(5.7m)(6.5m)(7.2m)

Total Equity

131.0m137.6m142.5m146.2m148.2m149.3m146.5m144.3m142.9m129.4m120.9m114.7m88.5m86.6m80.6m71.6m67.0m64.9m58.4m57.1m57.0m44.5m41.0m37.6m30.6m29.0m27.4m

Debt to Equity Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0.1 x0 x0 x0 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0.1 x0 x0 x0 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0 x0 x

Financial Leverage

1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x1.2 x1.2 x1.3 x1.3 x1.4 x1.4 x1.4 x1.3 x1.3 x1.3 x1.3 x1.4 x1.4 x1.4 x1.5 x1.5 x1.5 x

China Pharma Holdings Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q4, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

5.1m15.1m19.3m2.8m4.6m5.9m(2.8m)(7.3m)(9.6m)50.4k(11.0m)(17.4m)(4.1m)(6.8m)(9.2m)(1.6m)(4.0m)(5.8m)(966.9k)(3.3m)(5.5m)(293.5k)(1.3m)(3.2m)(417.7k)(1.3m)(2.0m)(660.9k)(647.8k)

Depreciation and Amortization

1.1m1.2m365.2k729.2k1.1m350.5k697.5k1.0m34.0k596.8k1.0m951.2k1.9m2.8m857.2k1.7m2.6m815.4k1.6m2.4m861.4k1.7m2.5m795.5k1.6m2.3m655.9k1.3m

Accounts Receivable

9.7m11.4m5.2m26.5k73.6k(589.2k)(1.7m)(1.1m)185.3k3.4m3.0m1.4m2.4m2.6m61.1k534.4k709.3k261.4k(6.3k)(305.2k)

Inventories

274.3k2.9m2.6m4.6m5.9m(1.9m)(1.7m)61.5k(4.8m)(7.7m)(396.5k)(2.5m)(3.3m)(2.0m)(2.8m)(3.2m)(549.5k)439.9k1.2m427.7k57.9k472.0k389.6k960.9k1.4m(24.7k)(14.1k)

Accounts Payable

(1.9m)(1.9m)2.7m1.8m1.7m122.4k1.4m376.3k(399.0k)714.4k1.3m917.8k1.2m2.1m888.2k105.3k739.6k(206.6k)(974.2k)(1.3m)196.4k35.2k(516.3k)6.1k223.6k130.6k(505.1k)(323.5k)

Cash From Operating Activities

5.4m5.2m119.7k1.9m3.0m1.1m3.1m3.7m(253.4k)2.4m2.6m(2.2k)(515.7k)652.0k1.3m554.9k1.4m9.8k(773.6k)(95.5k)523.7k124.4k1.0m90.5k931.8k1.4m(244.2k)(152.7k)

Purchases of PP&E

280.6k352.4k7.9k67.7k81.4k4.4k49.0k(4.6m)(39.2k)(66.2k)(86.3k)(51.8k)(67.3k)(3.6k)(30.0k)(33.3k)(73.9k)(73.5k)(85.7k)(347.8k)(840.4k)

Cash From Investing Activities

(4.7m)(5.6m)(798.0k)(1.3m)(2.4m)(404.4k)(4.6m)(9.8m)(200.0k)(4.5m)(4.9m)(47.1k)(264.9k)(3.3k)(39.2k)(66.2k)(86.3k)(26.6k)(51.8k)(67.3k)(3.6k)(30.0k)(33.3k)(73.9k)(73.5k)(85.7k)(347.8k)(840.4k)

Short-term Borrowings

Dividends Paid

38.1k

Cash From Financing Activities

347.9k595.7k293.0k393.0k6.4m(38.1k)605.3k604.8k(305.8k)(306.0k)(3.8m)(145.2k)(145.7k)(1.5m)(157.3k)(157.1k)(2.3m)(267.8k)(378.7k)(1.7m)(107.0k)1.9m

Net Change in Cash

1.2m358.8k(731.0k)820.7k1.0m720.8k(1.5m)475.8k(491.6k)(1.6m)(1.7m)(26.9k)(770.8k)421.7k1.0m36.5k(2.6m)(142.3k)(920.2k)(1.5m)437.8k(94.7k)(1.4m)(225.3k)469.3k(425.0k)(707.9k)851.7k

Interest Paid

179.5k248.0k75.6k151.7k228.9k111.3k167.8k324.1k621.8k943.3k310.4k629.4k905.2k1.2m486.2k689.8k139.0k410.5k410.5k125.7k125.7k351.2k80.7k179.0k241.5k57.0k118.4k

Income Taxes Paid

1.6m4.5m274.6k588.7k1.3m1.6m1.7m2.5m

China Pharma Holdings Ratios

USDQ2, 2011

Financial Leverage

1.1 x